OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon
Renata Spezani, Carlos Alberto Mandarim‐de‐Lacerda
Life Sciences (2021) Vol. 288, pp. 120188-120188
Open Access | Times Cited: 17
Renata Spezani, Carlos Alberto Mandarim‐de‐Lacerda
Life Sciences (2021) Vol. 288, pp. 120188-120188
Open Access | Times Cited: 17
Showing 17 citing articles:
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 4, pp. 311-319
Open Access | Times Cited: 123
Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 4, pp. 311-319
Open Access | Times Cited: 123
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Harold Bays, Angela Fitch, Sandra Christensen, et al.
Obesity Pillars (2022) Vol. 2, pp. 100018-100018
Open Access | Times Cited: 47
Harold Bays, Angela Fitch, Sandra Christensen, et al.
Obesity Pillars (2022) Vol. 2, pp. 100018-100018
Open Access | Times Cited: 47
GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?
Georgios S. Papaetis
Archives of Medical Science - Atherosclerotic Diseases (2023) Vol. 8, Iss. 1, pp. 19-34
Open Access | Times Cited: 19
Georgios S. Papaetis
Archives of Medical Science - Atherosclerotic Diseases (2023) Vol. 8, Iss. 1, pp. 19-34
Open Access | Times Cited: 19
The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice
Pedro H. Reis‐Barbosa, Ilitch Aquino Marcondes‐de‐Castro, Thatiany de Souza Marinho, et al.
Clinics and Research in Hepatology and Gastroenterology (2022) Vol. 46, Iss. 6, pp. 101922-101922
Closed Access | Times Cited: 25
Pedro H. Reis‐Barbosa, Ilitch Aquino Marcondes‐de‐Castro, Thatiany de Souza Marinho, et al.
Clinics and Research in Hepatology and Gastroenterology (2022) Vol. 46, Iss. 6, pp. 101922-101922
Closed Access | Times Cited: 25
GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons
Georgios S. Papaetis, Angelos Kyriacou
Advances in Clinical and Experimental Medicine (2022) Vol. 31, Iss. 11, pp. 1265-1274
Open Access | Times Cited: 20
Georgios S. Papaetis, Angelos Kyriacou
Advances in Clinical and Experimental Medicine (2022) Vol. 31, Iss. 11, pp. 1265-1274
Open Access | Times Cited: 20
Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials
Bixin Deng, Tiechao Ruan, Wenting Lu, et al.
Endocrine (2024) Vol. 86, Iss. 1, pp. 15-27
Closed Access | Times Cited: 4
Bixin Deng, Tiechao Ruan, Wenting Lu, et al.
Endocrine (2024) Vol. 86, Iss. 1, pp. 15-27
Closed Access | Times Cited: 4
The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects
Yue Liu, Wei Chen, Xuemei He, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Yue Liu, Wei Chen, Xuemei He, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Cotadutide improves brown adipose tissue thermogenesis in obese mice
Renata Spezani, Ilitch Aquino Marcondes‐de‐Castro, Thatiany de Souza Marinho, et al.
Biochemical Pharmacology (2023) Vol. 217, pp. 115852-115852
Closed Access | Times Cited: 7
Renata Spezani, Ilitch Aquino Marcondes‐de‐Castro, Thatiany de Souza Marinho, et al.
Biochemical Pharmacology (2023) Vol. 217, pp. 115852-115852
Closed Access | Times Cited: 7
Cotadutide (GLP-1/Glucagon dual receptor agonist) modulates hypothalamic orexigenic and anorexigenic neuropeptides in obese mice
Renata Spezani, Thatiany de Souza Marinho, Thiago Santos Reis, et al.
Peptides (2023) Vol. 173, pp. 171138-171138
Closed Access | Times Cited: 5
Renata Spezani, Thatiany de Souza Marinho, Thiago Santos Reis, et al.
Peptides (2023) Vol. 173, pp. 171138-171138
Closed Access | Times Cited: 5
Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes
Anandan Palani, Andrea R. Nawrocki, Federica Orvieto, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 8, pp. 1248-1254
Open Access | Times Cited: 7
Anandan Palani, Andrea R. Nawrocki, Federica Orvieto, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 8, pp. 1248-1254
Open Access | Times Cited: 7
Pancreatic islet remodeling in cotadutide-treated obese mice
Renata Spezani, Thatiany de Souza Marinho, Luiz E.M. Cardoso, et al.
Life Sciences (2023) Vol. 327, pp. 121858-121858
Closed Access | Times Cited: 3
Renata Spezani, Thatiany de Souza Marinho, Luiz E.M. Cardoso, et al.
Life Sciences (2023) Vol. 327, pp. 121858-121858
Closed Access | Times Cited: 3
Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
Shubham Vishnoi, Shayon Bhattacharya, Erica M. Walsh, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 15, pp. 4934-4947
Open Access | Times Cited: 3
Shubham Vishnoi, Shayon Bhattacharya, Erica M. Walsh, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 15, pp. 4934-4947
Open Access | Times Cited: 3
Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?
Natalie Klempel, Keith Thomas, J. Michael Conlon, et al.
Peptides (2022) Vol. 157, pp. 170877-170877
Open Access | Times Cited: 5
Natalie Klempel, Keith Thomas, J. Michael Conlon, et al.
Peptides (2022) Vol. 157, pp. 170877-170877
Open Access | Times Cited: 5
Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity
Chunhui Huang, Anandan Palani, Zhiqiang Yang, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 8, pp. 1255-1261
Open Access | Times Cited: 3
Chunhui Huang, Anandan Palani, Zhiqiang Yang, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 8, pp. 1255-1261
Open Access | Times Cited: 3
Intramolecularly lactam stapled oxyntomodulin analogues inhibit cancer cell proliferation in vitro
Junli Wang, Cen Liu, Hongliu Yang, et al.
Chinese Chemical Letters (2022) Vol. 34, Iss. 4, pp. 107920-107920
Closed Access | Times Cited: 1
Junli Wang, Cen Liu, Hongliu Yang, et al.
Chinese Chemical Letters (2022) Vol. 34, Iss. 4, pp. 107920-107920
Closed Access | Times Cited: 1
GLP-1 Targeted Novel 3-phenyl-7-hydroxy Substituted Coumarins Mitigate STZ-induced Pancreatic Damage and Improve Glucose Homeostasis in OGTT Method
Mandeep Kumar Gupta, Rajnish Srivastava, Sushil Kumar, et al.
Protein and Peptide Letters (2022) Vol. 29, Iss. 11, pp. 979-992
Closed Access
Mandeep Kumar Gupta, Rajnish Srivastava, Sushil Kumar, et al.
Protein and Peptide Letters (2022) Vol. 29, Iss. 11, pp. 979-992
Closed Access
